Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age.

ABSTRACT:

Introduction

Mechanistic target of rapamycin (mTOR) inhibitors sirolimus and everolimus are an effective therapy for subependymal giant cell astrocytomas, cardiac rhabdomyomas, renal angiomyolipomas, and lymphangioleiomyomatosis associated with tuberous sclerosis complex (TSC). Everolimus was recently approved in the EU and the USA for the treatment of refractory focal-onset seizures. Despite frequent use of mTOR inhibitors, there are only a few studies on their effect on epilepsy control in children under 2 years of age. This study aims to assess the effect of adjunctive mTOR inhibitor treatment on seizure frequency in this age group.

Methods

We performed retrospective data analysis of medical records of patients with TSC who initiated sirolimus or everolimus under the age

SUBMITTER: Smialek D 

PROVIDER: S-EPMC10195938 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature